Zoetis - ZTS Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZTS shares.
View ZTS analyst ratings or view top-rated stocks.

7 brokerages have issued twelve-month price targets for Zoetis' shares. Their ZTS share price forecasts range from $180.00 to $260.00. On average, they predict the company's share price to reach $223.83 in the next year. This suggests a possible upside of 36.4% from the stock's current price.
View analysts price targets for ZTS or view top-rated stocks among Wall Street analysts.

Zoetis' stock was trading at $146.55 on January 1st, 2023. Since then, ZTS stock has increased by 12.0% and is now trading at $164.15.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our ZTS earnings forecast.

Zoetis Inc. (NYSE:ZTS) issued its earnings results on Tuesday, February, 14th. The company reported $1.15 earnings per share for the quarter, meeting analysts' consensus estimates of $1.15. The firm earned $2.04 billion during the quarter, compared to analyst estimates of $2.01 billion. Zoetis had a trailing twelve-month return on equity of 50.20% and a net margin of 26.16%. The firm's revenue was up 3.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.00 EPS.
Read the conference call transcript.

Zoetis announced a quarterly dividend on Wednesday, February 8th. Shareholders of record on Friday, April 21st will be paid a dividend of $0.375 per share on Thursday, June 1st. This represents a $1.50 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date of this dividend is Thursday, April 20th.
Read our dividend analysis for ZTS.

ETFs with the largest weight of Zoetis (NYSE:ZTS) stock in their portfolio include ProShares Pet Care ETF (PAWZ), VanEck Agribusiness ETF (MOO), iShares U.S. Pharmaceuticals ETF (IHE), VanEck Pharmaceutical ETF (PPH), IQ Winslow Focused Large Cap Growth ETF (IWFG), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and ClearBridge Large Cap Growth ESG ETF (LRGE).

Zoetis (NYSE:ZTS) pays an annual dividend of $1.50 per share and currently has a dividend yield of 0.91%. The company has been increasing its dividend for 9 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 33.33%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ZTS will have a dividend payout ratio of 25.04% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ZTS.

Zoetis issued an update on its FY 2023 earnings guidance on Tuesday, February, 14th. The company provided EPS guidance of $5.34-$5.44 for the period, compared to the consensus estimate of $5.33. The company issued revenue guidance of $8.57 billion-$8.72 billion, compared to the consensus revenue estimate of $8.57 billion.

50 employees have rated Zoetis Chief Executive Officer Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among the company's employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

Zoetis' stock is owned by many different institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (4.19%), Morgan Stanley (2.33%), Geode Capital Management LLC (2.08%), Price T Rowe Associates Inc. MD (1.73%), Polen Capital Management LLC (1.20%) and Clearbridge Investments LLC (1.12%). Insiders that own company stock include Catherine A Knupp, Glenn David, Gregory Norden, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Linda Rhodes, Robert Edward Kelly, Robert W Scully, Roman Trawicki, Roxanne Lagano and Willie M Reed.
View institutional ownership trends.

Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ZTS stock can currently be purchased for approximately $164.15.

Zoetis (NYSE:ZTS) has a market capitalization of $76.07 billion and generates $8.08 billion in revenue each year. The company earns $2.11 billion in net income (profit) each year or $4.50 on an earnings per share basis.

The company employs 13,800 workers across the globe.

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The official website for the company is www.zoetis.com. The company can be reached via phone at (973) 822-7000, via email at steve.frank@zoetis.com, or via fax at 302-655-5049.